ChronoScale Corporation Q1 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

Ekso Bionics Q1 2024 Earnings Summary

Revenue & Device Sales: Generated $3.8 million in revenue (down from $4.1 million in Q1 2023). Sold 29 EksoHealth devices, impacted by typical seasonality and IDN procurement fluctuations.

Financial Highlights (vs Q1 2023)

  • Gross Profit: $2.0 million (flat YoY); Gross margin improved to 52% from 49%, primarily due to lower EksoHealth device and service costs.
  • Operating Expenses: $5.2 million, down 19% from $6.4 million, driven by reduced legal expenses, headcount, and absence of HMC acquisition/integration costs.
  • Net Loss: $3.4 million ($0.20 per basic/diluted share), improved from $4.4 million ($0.33 per share).
  • Cash Position: $8.8 million (including restricted cash) as of March 31, 2024, up from $8.6 million as of December 31, 2023.

Key Business Updates

  • EksoHealth (Rehabilitation): Focused on IDN network growth and larger multi-unit deals. Pipeline solid with ~$1 million backlog from Q1 (to be recognized in 2024). International momentum strong, especially EMEA due to French public health system's adoption of robotics in neurorehabilitation.
Professional feature The full AI summary covers key highlights, financial performance and analyst Q&A.
Operator: Greetings, and welcome to the Ekso Bionics First Quarter 2024 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Matt Steinberg with Finn Partners. Thank you. You may begin. Matt Steinberg: Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; Jerome Wong, Chief Financial Officer; and Jason Jones, Chief Operating Officer. Earlier today, Ekso Bionics released financial results for the quarter ended March 31, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations or our expectations of the regulatory landscape governing our products and operations, are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materi
Professional feature The full transcript includes every speaker turn.